CREID Network: Pilot Research Program
2022 Call for Applications
https://creid-network.org/pilot-program

Responses to Questions
November 15, 2021

Question	Response
Regarding the CREID pilot program, is it expected/acceptable that there be a budget for the RC collaborating site that will assist the pilot site in establishing the study? I have an inquiry about a Co-PI study that would include a team member already associated with the CREID. The CREID member is a junior investigator/post-doc that will work with the international Co-PI/team on the study. I know Co-PIs are allowable but I wasn't sure if we could have the Co-PI already associated with the Center.	It is definitely acceptable to have an eligible Co-PI at the RC that will co-lead study. Please just note that separate awards will have to be made to each of the Co-PI's institutions/ organizations in that case, with both awards combined totaling the $150K award limit. Also, both the Co-PIs must be investigators that meet the award eligibility criteria. Please also note there is a limit of up to two Co-PIs.
Our research team is planning to apply for the CREID Research Pilot Program, and we couldn't find all the contact email for each Research center for collaboration. If you have their contact information, please let me know.	Contact information for each Research Center is on the CREID Website on the Research Center pages. On the navigation pane, you can find the list of each Research Center and their webpages.

Question	Response
I came across The CREID Network Pilot Research Program call for applications, which supports, trains, and mentors the next generation of emerging infectious disease researchers. I understand a webinar was held on this application but I missed it. I would be grateful if the recorded version is sent to me via this mail. This will give me the opportunity to understand what's expected of me as an applicant. I will also want to find out the procedure in getting in touch with a collaborator from CREID to enable me to be in good standing for the application. I look forward to hearing from you.	The webinar and application guidelines are posted on the CREID website here: https://creid-network.org/pilot-program. The purple navigation panel at the top of the page has a drop-down menu for Research Centers. There you will find webpages for each Research Center alongside contact information.
I am from an LMIC but currently I am working as a post doc at university in the US. Am I still eligible as someone from LMIC even that I would execute the research during my post doc in the USA?	Please carefully review the eligibility criteria to determine your eligibility. Being from an LMIC is not the only eligibility criteria.
To apply for the Pilot Research Program 2022, I must have a collaboration with one of CREID PI's, once I would be working from another institution. Does this collaboration must be established with someone in one of the research centers or with someone from the research sites would also be a possibility? I thought that would be interesting if I could collaborate with one of the research sites in the LMIC I am from, but I'm not sure if this would be a possibility according to the rules of the application.	We require all applicants to have a formal collaboration with a CREID Research Center. Please contact one or more CREID Research Centers to discuss your research interests. Contact information is on the CREID Website on the Research Center pages.
I have not received any grants listed under the following link in the NIH website: List of smaller grants & awards that maintain ESI status | grants.nih.gov Therefore, can I apply under the "New Investigator" category? Or is the LMIC category more suitable?	Please carefuly review the eligibility criteria included in the Call for Applications and discuss with the collaborating Research Center you will be applying under to determine if you meet the requirements.

Question	Response
I need some assistance in identifying the category of eligibility for me. I have not received any grants listed under the following link in the NIH website: List of smaller grants & awards that maintain ESI status | grants.nih.gov Therefore, can I apply under the "New Investigator" category? Or is the LMIC category more suitable?	Please carefuly review the eligibility criteria included in the Call for Applications and discuss with the collaborating Research Center you will be applying under to determine if you meet the requirements.
Does a project about Human Papillomavirus infections could be eligible and belong to the research priorities for the CREID program?	Please discuss this with the collaborating Research Center you will be applying under to determine if this falls under their research priorities.
• I am originally from Brazil and I was wondering if I would still be considered a LMIC candidate despite working in the US. • Is it ok to have a collaboration with a CREID research site, or the collaboration must be with a CREID research center? Since I am from Brazil I thought it would be nice to collaborate with one of the research sites in Brazil.	Please carefuly review the eligibility criteria included in the Call for Applications and discuss your interest in collaborating with one of the CREID research sites with one of the CREID Research Centers. Each Research Center is limited to supporting up to 3 applicants for this round of funding.
I wish to register for your pilot research program. Please kindly provide me with directions.	Please carefully review the requirements for the Pilot Research Program on the website (https://creid-network.org/pilot-program) and connect with one of the CREID Research Centers to determine collaboration opportunities.

Is there an issue with a proposal, and what authorization is necessary to work with possible CCHF specimens (tick) in BSL-3, due to it being a US Federal Select Agent? These specimens will be used for isolation of nucleic acids for detection and sequencing CCHF, but not culturing or isolating the virus. Also note the possibility of CCHS was included in the original Research Center application, and they are out target sponsor, although they did not yet seek US Federal Select agent approval for working with CCHF as of yet.	There are no issues with applying for pilot funding in this case. The exemption request is a reasonable path forward as long as you follow the rules pasted below (sources linked at the bottom of the email) and can ensure compliance with DMID and with local entities prior to award. The CREID Network has multiple Approved Select Agent Entities that could receive and store material via approved transfer process if that is needed. **§ 121.5 Exemptions for VS select agents and toxins.** (a) Diagnostic laboratories and other entities that possess, use, or transfer a VS select agent or toxin that is contained in a specimen presented for diagnosis or verification will be exempt from the requirements of this part for such agent or toxin contained in the specimen, provided that: (1) Unless directed otherwise by the Administrator, within 7 calendar days after identification of the select agent or toxin, the select agent or toxin is transferred in accordance with § 121.16 or destroyed on-site by a recognized sterilization or inactivation process; (2) The agent or toxin is secured against theft, loss, or release during the period between identification of the agent or toxin and transfer or destruction of such agent or toxin, and any theft, loss, or release of such agent or toxin is reported; (3) Unless otherwise directed by the Administrator, the clinical or diagnostic specimens collected from a patient infected with a select agent are transferred in accordance with § 121.16 or destroyed on-site by a recognized sterilization or inactivation process within 7 calendar days after delivery of patient care by heath care professionals has concluded; and (4) The identification of the agent or toxin is reported to APHIS or CDC, the specimen provider, and to other appropriate authorities when required by Federal, State, or local law by telephone, facsimile, or email. This report must be followed by submission of APHIS/CDC Form 4 to APHIS or CDC within 7 calendar days after identification. (b) Diagnostic laboratories and other entities that possess, use, or transfer a VS select agent or toxin that is contained in a specimen presented for proficiency testing will be exempt from the requirements of this part for such agent or toxin contained in the specimen, provided that: (1) Unless directed otherwise by the Administrator, within 90 calendar days of receipt, the agent or toxin is transferred in accordance with § 121.16 or destroyed on-site by a recognized sterilization or inactivation process; (2) The agent or toxin is secured against theft, loss, or release during the period between identification of the

	agent or toxin and transfer or destruction of such agent or toxin, and any theft, loss, or release of such agent or toxin is reported; and (3) The identification of the agent or toxin, and its derivative, is reported to APHIS or CDC. To report the identification of a select agent or toxin, APHIS/CDC Form 4 must be submitted within 90 days of receipt of the agent or toxin. A copy of the completed form must be maintained for 3 years. (c) Diagnostic reagents and vaccines that are, bear, or contain VS select agents or toxins that are produced at USDA diagnostic facilities will be exempt from the requirements of this part. (d) Unless the Administrator by order determines that additional regulation is necessary to protect animal health or animal products, products that are, bear, or contain VS select agents or toxins will be exempt from the requirements of this part if the products have been cleared, approved, licensed, or registered pursuant to: (1) The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 *et seq.*); (2) Section 351 of Public Health Service Act (42 U.S.C. 262); (3) The Virus-Serum-Toxin Act (21 U.S.C. 151-159); or (4) The Federal Insecticide, Fungicide, and Rodenticide Act (7 U.S.C. 131 *et seq.*). (e) The Administrator may exempt from the requirements of this part an experimental product that is, bears, or contains a VS select agent or toxin if such product is being used in an investigation authorized by any Federal law and the Administrator determines that additional regulation under this part is not necessary to protect animal health or animal products. To apply for an exemption, an individual or entity must submit APHIS/CDC Form 5. A written decision granting or denying the exemption will be issued. The applicant must notify APHIS when an authorization for an investigation no longer exists. This exemption automatically terminates when such authorization is no longer in effect. (f) In addition to the exemptions provided in paragraphs (a) through (e) of this section, the Administrator may grant a specific exemption upon a showing of good cause and upon his or her determination that such exemption is consistent with protecting animal health or animal products. An individual or entity may request in writing an exemption from the requirements of this part. If granted, such exemptions are valid for a maximum of 3 years; thereafter, an individual or entity must request a new exemption. If a request for exemption is denied, an individual or entity may request reconsideration in writing to the Administrator. The

Question	Response
	request for reconsideration must state all of the facts and reasons upon which the individual or entity relies to show that the exemption was wrongfully denied. The Administrator will grant or deny the request for reconsideration as promptly as circumstances allow and will state, in writing, the reasons for the decision. [70 FR 13284, Mar. 18, 2005, as amended at 73 FR 61331, Oct. 16, 2008; 77 FR 61078, Oct. 5, 2012; 79 FR 26831, May 12, 2014; 82 FR 6208, Jan. 19, 2017]